Drug Profile
CTX 101 - Crescita Therapeutics
Alternative Names: CTX-101 - Crescita Therapeutics; Mical (1); Mical 1Latest Information Update: 25 Apr 2022
Price :
$50
*
At a glance
- Originator Nuvo Research
- Developer Crescita Therapeutics; Ferndale Laboratories
- Class Antipsoriatics; Corticosteroids; Heart failure therapies; Stem cell therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Plaque psoriasis
- No development reported Psoriasis
Most Recent Events
- 25 Apr 2022 CTX 101 is still in phase III development in Plaque psoriasis in USA (Topical) (Crescita Therapeutics pipeline, April 2022)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Psoriasis in Canada (Topical)
- 18 Sep 2017 Phase-II clinical trials in Plaque psoriasis in USA (Topical), before September 2017